TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05705934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Each session of the exercise program will last 50 minutes and will consist of 4 stages. At these stages, it is aimed to work the social, physical, spiritual and mental parameters of the holistic approach.
Study: NCT05671146

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-gravity treadmill
Description: participants will perform exercises with partial weight-bearing by using an anti-gravity treadmill

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight-bearing exercises for knee flexors and extensors
Description: Stretching and strengthening exercises will be performed in a weight-bearing position

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non weight-bearing exercises for knee flexors and extensors
Description: Stretching and strengthening exercises will be performed in a non-weight-bearing position
Study: NCT06300463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV Q6W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 450 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 450 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 450 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGEN1423
Description: 30 mg/kg IV Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 8Gy x 3 between Day 0 - 18; Allowed techniques for radiation are 3D conformal, intensity modulated radiotherapy (IMRT), or SBRT
Study: NCT05068297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incrediwear Germanium-Embedded Knee Brace following ACL reconstruction
Description: Germanium-Embedded Knee Brace will be applied to the effected limb following ACL reconstruction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replica Knee Brace
Description: Replica Knee brace will be applied to the effected limb following ACL reconstruction
Study: NCT05438862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: State of art aortic valve surgery
Description: Optimal surgical treatment (aortic valve-sparing surgery, aortic valve replacement, Ross procedure).
Study: NCT05874635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Device
Description: Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
Study: NCT05444153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 1 tablet of oral semaglutide once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Participants will receive 1 tablet of empagliflozin once daily.
Study: NCT06271629

Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index
Description: The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties.

Intervention type: DIAGNOSTIC_TEST
Intervention: Insomnia severity index
Description: The ISI score is a self-report questionnaire consisting of 7 items designed to assess the nature, severity, and impact of insomnia.(16) The typical recall period for respondents is the last month. The evaluated dimensions include the severity of sleep onset, sleep maintenance, and early morning awakening problems, as well as sleep dissatisfaction, interference of sleep difficulties with daytime functioning, noticeability of sleep problems by others, and the distress caused by the sleep difficulties.
Study: NCT04953325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 Vaccine
Description: 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Inactivated Hepatitis A Vaccine
Description: 500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.
Study: NCT04975477

Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy and liver stiffness
Description: Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.

Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy and liver stiffness
Description: Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.

Intervention type: PROCEDURE
Intervention: Esophagogasrtoduodendoscopy and liver stiffness
Description: Time frame between elastography measurement and esophagogastroduodendoscopy is within 6 months.

Intervention type: PROCEDURE
Intervention: hepatic venous pressure gradient
Description: A method was used to evaluate portal pressure.
Study: NCT05577884

Intervention type: DIAGNOSTIC_TEST
Intervention: noncontrast-enhanced whole-body CT
Description: noncontrast-enhanced low-dose whole-body CT using dual-source CT scanner using A-tube (75% radiation) and B-tube (25% radiation).~* conventional low-dose CT data (A +B tubes, 100% dose) are reconstructed with iterative reconstruction~* ultra-low dose CT data (B-tube only, 25% dose) are reconstructed with deep learning commercially available software.
Study: NCT05986747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based CBT guided self-help Interventions
Description: Seven modules were developed from the corresponding modules of self help. Each video was of 3-5 minutes duration. Each week 2-3 videos will be sent to participants through secure WhatsApp connection. Participants received daily reminders in the form of short pre-recorded audio messages through whatsapp.~Trained RAs will provide guidance as well as technical assistance during the intervention period. They will call participants once a week for 15 minutes. This call will include, feedback from previous session, explanation of current week and discussion on home work assignments.
Study: NCT05566977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous adoptive T regulatory cell transfer.
Description: Identification and count, using flowcytometry, for human Tregs will be based on both positive and negative cell markers, human Tregs are (CD4+, CD25+, CD127-, Foxp3+). Peripheral heparinized venous blood will be used .GMP-Compliant Protocol for the Isolation and Expansion of Tregs for Clinical Application .Cryopreservation of Expanded Tregs .Administration of T reg cells and follow-up of adverse events.
Study: NCT05273697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater Cold Snare Polypectomy
Description: The procedure of Underwater Cold Snare Polypectomy (UP) will be as follows:~1. Complete suction of air from the intestinal tract~2. Partial opening of the intestinal lumen by using sterile room temperature water via a water pump~3. Complete immersion of the lesion in water~4. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~5. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cold Snare Polypectomy
Description: The procedure of Conventional Cold Snare Polypectomy (CCSP) will be as follows:~1. If the entry during the endoscopy has been made with water, the water will be aspirated, and the intestinal lumen will be re-stretched using air / CO2~2. Snaring of the lesion and a small amount of surrounding healthy tissue (1-2mm)~3. Excision The objective will be the en bloc resection of the lesion including healthy tissue (about 2mm). If the en bloc resection fails, a piecemeal will be performed on as few specimens as possible
Study: NCT06093854

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Description: Intraoperative radiotherapy (IORT, 15-20 Gy, 20-50min)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Description: postoperative stereotactic body radiotherapy (SBRT, 30Gy, 5 fractions, 3 weeks)
Study: NCT06064175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Patients will receive ibuprofen 400 mg/4 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Patients will receive ibuprofen 800 mg/8 ml via the parenteral route as a rapid 10-minute infusion in 150 ml of saline solution (0.09% NaCl).
Study: NCT06208969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive nutrition counseling
Description: individualized regular nutrition education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intensive nutrition counseling
Description: individualized regular nutrition education
Study: NCT06064214

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: u/s guided intermediate cervical plexus block
Description: The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: u/s guided intermediate cervical plexus block
Description: The patient will be placed in supine position,u/s probe is placed on the lateral neck, overlying the sternomastoid muscle at the level of its midpoint , Once the SCM has been identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen.cervical plexus is visible as a small collection of hypoechoic nodules ( immediately superficial to the prevertebral fascia the needle is passed through the skin, platysma, and investing layer of the deep cervical fascia, and the tip is placed adjacent to the plexus,bupivicaine 0.25% (5-15 mL) is administered to envelop the plexus
Study: NCT05149911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Coaching
Description: Sessions with a professional life coach.
Study: NCT06158399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine in combination with R-CHOP
Description: Specified dose on specified days:~Azacitidine (A) 100mg subcutaneous d-1 to d-5 Rituximab (R) 375mg/m2 IV d0 Cyclophosphamide (C) 750mg/m2 IV d1 epirubicin (H) 75mg/m2 IV d1 or liposomal adriamycin (D) 25-30mg/m2 IV d1 Vincristine (O) 1.4mg/m2 (max 2mg) IV d1 Prednisone (P) 100mg orally d1-5
Study: NCT05216549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-based exercise
Description: 8 weeks x 2 times per week for 45 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Land-based exercise
Description: 8 weeks x 2 times per week for 45 min
Study: NCT05087706

Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib 400mg qd po

Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib 400mg qd po

Intervention type: DRUG
Intervention: Bicalutamide
Description: Bicalutamide was administered orally at a daily dose of 50 mg

Intervention type: DRUG
Intervention: Bicalutamide
Description: Bicalutamide was administered orally at a daily dose of 50 mg

Intervention type: DRUG
Intervention: Leuprorelin
Description: Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks

Intervention type: DRUG
Intervention: Leuprorelin
Description: Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks
Study: NCT04732494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ociperlimab
Description: Ociperlimab is a monoclonal antibody formulated for intravenous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.
Study: NCT06436157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced education
Description: In addition to the education conducted as part of usual care, the nurse will: 1) provide basic education on GCT; and 2) if the patient is eligible and agreeable to GCT, place a referral to GCT (if not already ordered).~Patients will also be provided with written materials reinforcing the key messages of GCT education, designed to be understandable to individuals without a medical background. Nurses will also conduct a follow-up nudge by sending an in basket message via electronic medical record to ensure that the referrals are processed by the referral coordinators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care education
Description: A brief introduction to GCT will be provided in accordance with the information covered in the chemo education binder, which is the current standard of care at Enloe Regional Cancer Center. As per the usual care, referrals for genetic testing will be clinician-initiated without the proactive involvement of the RN.
Study: NCT05761782

Intervention type: BEHAVIORAL
Intervention: Education
Description: To educate catchment area residents on modifiable risk factors for cancer (e.g., screening, behavior, vaccination) and the importance of participation in cancer research. Provide participants with educational materials on cancer prevention, screening, and vaccination.
Study: NCT05406830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: The special type of acupuncture needles will be inserted into the skin of standard acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: health education
Description: According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health education
Description: According to the Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia related Diseases in China and the 2012 Guidelines of the American College of Rheumatology, health education should be given as basic prevention. These include weight control, regular exercise, limiting alcohol and high-purine and high-fructose diets, encouraging dairy and fresh vegetables and drinking moderate amounts of water, and not recommending or limiting soy products.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: We will use a non-insertive sham control. Sham points are located at 5 cun lateral to the seventh, eighth, ninth, tenth, eleven and twelve thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun.
Study: NCT05999097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Short Chain Fructooligosaccharides
Description: The intervention will receive Short-Chain Fructooligosaccharides at a dose of 12 gr. every 24 hours diluted in 250 ml of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: This group will receive 12 g of corn starch as a control group.
Study: NCT05977504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Psychological Empowerment Courses
Description: 9 times online course and 3-days workshop for 6 months of psychological Empowerment Courses.
Study: NCT06071260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drop
Description: One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.
Study: NCT06445426

Intervention type: DEVICE
Intervention: Cystometry
Description: The procedure will be done according to the International Continence Society's (ICS) recommended indications for the procedure. The investigational device is inserted into a 12F single-use hydrophilic catheter. After correct positioning is verified by ultrasound and x-ray, the investigational device is released from the insertion catheter. The insertion catheter is then carefully removed, securing the correct positioning of the investigational device inside the bladder. The investigational device is connected to a data logger. In the conventional device, the intravesical pressure is recorded using a water perfused 3F catheter with a 3 ml/hour perfusion rate. The 3F catheter is hooked on an 8F catheter to facilitate introduction into the bladder. The catheters used for pressure transmission are connected to external transducers and a computer with software processing the recording
Study: NCT04568616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: Aromatase Inhibitor
Study: NCT06023238

Intervention type: PROCEDURE
Intervention: Treatment of Chronic TKA PJI
Description: Patients will all undergo standard of care treatment for a chronic total knee arthroplasty prosthetic joint infection.
Study: NCT06368635

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: target vessel with intermediate coronary lesion (40-80% diameter stenosis and FFR(fractional flow reserve) ≥0.8； or severe stenosis（\>80%）after successful PCI(percutaneous coronary intervention) and FFR ≥0.8
Study: NCT06310876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: • single oral Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: • single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: • single oral dose
Study: NCT05873751

Intervention type: BIOLOGICAL
Intervention: Trumenba Vaccine
Description: Trumenba vaccine given as standard of care

Intervention type: BIOLOGICAL
Intervention: MenACWY Vaccine
Description: MenACWY Vaccine given as standard of care

Intervention type: BIOLOGICAL
Intervention: MenACWY Vaccine
Description: MenACWY Vaccine given as standard of care
Study: NCT06191796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanzalintinib
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanzalintinib
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanzalintinib
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanzalintinib
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB521
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB521
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB521
Description: Specified doses on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB521
Description: Specified doses on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses on specified days